antidiabetic review_revised draft sep 14, 2014 zh to ka.docx
TRANSCRIPT
Review article: Nutrition Reviews
The Potential of Fruits Flavonoids as Antidiabetic Agents
Institute of Food Science and Nutrition, University of Sargodha, Sargodha, Pakistan
*Corresponding author: Umar Farooq
Assistant Professor
Institute of Food Science and Nutrition
University of Sargodha, Sargodha, Pakistan.
Phone: +923227149412, Fax: +92489230316
E-mail: [email protected]
1
1
2
3
4
5
6
7
8
9
10
11
12
13
1415
Diabetes mellitus is a global disorder, and major issue for health care systems. The onset of
diabetes mainly depends upon genetics and lifestyle. Currently used therapeutic options for
diabetes mellitus, like dietary amendments, oral hypoglycemic drugs, and insulin have their own
limitations. Recently, antidiabetic effect of fruits flavonoids has been studied due to their
property of managing the altered glucose and oxidative metabolisms of in diabetic state. The
current review outlooks the use of fruits flavonoids as an alternative in the prevention of diabetes
mellitus.
Keywords: Diabetes mellitus, fruits, flavonoids, antidiabetic
2
16
17
18
19
20
21
22
23
24
INTRODUCTION
DIABETES: PREVALENCE, ETIOLOGY AND CONSEQUENCES
Diabetes mellitus is one of the most common metabolic disorders with 382 million patients
globally estimated till 2013.N -1 The personal and public health problem of diabetes is
continuously escalating exponentially (2.6 % annually) throughout the world N-2, and according to
World Health Organization, diabetes will be the 7th leading cause of death in 2030. N - 3
Symptomatically, diabetes mellitus is characterized by chronic hyperglycaemia (elevated
concentration of glucose in the blood ≥ 7.0 mmol/L or 126 mg/dl). N - 4 Other symptoms includes
but not limited to severe thirst (polydipsia), frequent urination (polyurea), increased hunger
(polyphagia), unconsciousness, weight loss and coma leading to death or many medical
complication may occur in the absence of effective treatment. This worldwide rapidly growing
health threat occurs due to multiple interaction and combination of multiple genetic and
environmental factors Diabetes mellitus (metabolic disorder) occurs because of complex
interactions between multiple genetic and environmental factors.1
Diabetes has complex and various degrees of heterogeneity in its etiology. Evidently, diabetes
manifested when the body becomes resistant to insulin (a hormone secreted by β-cells of
pancreas gland) or when enough insulin is not produced to regulate glucose metabolism.N-5 Type
1 diabetes and type 2 diabetes are two main types of this disease 4,5 besides other similar
conditions like pre-diabetes (impaired glucose regulation) and gestational diabetes. In type 1
diabetes (insulin dependent diabetes mellitus or juvenile diabetes) body cannot produce insulin
due to autoimmune or infectious destruction of β-cells of pancreas gland and insulin is required
to be externally administered.N - 6 Type 2 diabetes, previously known as non insulin dependent
3
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
diabetes mellitus, is characterized by body’s ineffective use of insulin N - 7 and is the most common
and prevalent form (90-95 %) of diabetes mellitus.
Exact mechanism of the development and progression of diabetes is still unclear. It is postulated
that diabetes occurs when the tightly controlled mechanisms have been disturbed due to any
reason. Notable increase has been seen in the identification of the molecular components and all
the signaling pathways used in the regulation of glucose absorption.6 Chronic hyperglycaeima
affects nerves system, heart, kidneys, eyes and other systems of body. Diabetes is the leading
cause of many disease conditions like storkes, cardiovascular disease, renal failure, visual
impairment and blindness, lower limb amputations, erectile dysfunction, insignificant wound
healing.2,3, N - 8 , N - 9 , N - 10 , N - 11 , N - 12 , N - 13 Sometimes diabetes is not diagnosed until the development of
other health problems. Stress, lethargy life style, smoking, hypertension, eating habits,
processing and nutritional composition of food are some of the predisposing environmental
factors in the development of diabetes mellitus. N - 14 , N - 15 , N - 1 6 On the food and nutrition fore front;
refined grains, highly processed food, energy dense junks, saturated fat, excessive alcohol, sugar
sweetened beverages are major culprits.N-1 7 , N-1 8
This metabolic disorder is described as the high level of blood sugar due to defects in insulin
secretion or insulin action.
Erectile dysfunction, insignificant wound healing, blindness, kidney failure, and heart diseases
are the main problems related to long-term diabetes and these problems increases as the disease
progresses.2,3 The two main types of this disease are: type 1 diabetes (insulin is externally
administered) and type 2 diabetes (use of oral antihyperglycemic drugs and externally
4
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
administered insulin).4,5 Notable increase has been seen in the identification of the molecular
components and all the signaling pathways used in the regulation of glucose absorption.6
MANAGEMENT OF DIABETES
Diabetes is life long disease and no cure for diabetes is yet to be found however, different
pharmacological and non-pharmacological therapeutic measures have positively been employed
to enhance the life quality of individuals suffering from diabetes and its micro and macro-
vascular complications.15 As diabetes is characterized by chronically increased levels of blood
glucose thus main theme of current diabetes management is to better regulate the glucose
metabolism.N-19 However, this is not so simple, this complex disorder needs continuous medical
attention, support, and self-management education of the patient to avoid serious complications
and to diminish the risk of long-term complications; accordingly its management is multifarious
and needs many issues, beyond glycemic control, to be addressed.16 Lifestyle interventions
addressing diet and physical activity are considered a first-line intervention for the prevention of
type 2 diabetes.N-20
Insulin is routinely administered in type 1 diabetes mellitus patients due to auto-destruction of β-
cells of pancreas and ultimately incapability of cells to secrete insulin and for type 2 diabetic
patients, in which cells are unable to respond the normal action of circulating insulin and
incapable to meet safe glycemic targets.17 Some compounds possessing antidiabetic properties
have been extensively employed to manage disbetes.N-6, 7 Several surgical procedures (bariatric
surgery) are adopted mainly to achieve weight loss in obese persons to mange diabetes especially
when the lifestyle and pharmacologic interventions become unable to control type 2 diabetes or
its related problems.24 Different degrees and proportions of survival benefits are reported with
5
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
bariatric surgery,N-21 however no considerable improvement had been witnessed in highly
vulnerable population N-22 and there are also reports of reoccurrence of obesity and associated
problems like obesity after surgical interventions depending upon pre-bariatric history of
diabetes.N-23
The clinical evaluation of a patient helps to select the suitable therapy for the treatment. All the
above mention preventive measures fulfill their objective to some extent except bariatric
surgery24 and diabetes and it related complications are not cured till now. Efficient and
sustainable management of diabetes is becoming more important with rapidly increasing
morbidity due to this disease globally.N-3 It is predicted that by year 2035 patients suffering from
diabetes would reach to 600 million worldwide. N-1
COMMONLY USED ANTI-DIABETES AGENTS AND THEIR RELATED PROBLEMS
Recently used therapeutic anti-diabetes agents measures for diabetes comprise of insulin
and several other oral antidiabetic agents likeare sulfonylureas, glinides, biguanides, and α-
glucosidase inhibitors.7 They are used asemployed singly or in combine form. to attain better
glucose regulation. Most of these oral antidiabetic agents impose serious side effects so, diabetes
management without any adverse effect is still a challenge.8 Therefore, the exploration of more
active and safer therapeutic agents in eliminating diabetic syndromes is an important area of
investigation.9
Natural products from fruit and vegetable sources are becoming popular worldwide and
broadly accepted as an aide to conventional therapy.10 Increasing public awareness and scientific
interest headed the research towards the evaluation of fruits role in health up-gradation and
disease treatment. In recent years, great attention has been focused on the antidiabetic role of
6
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
bioactive components of fruits known as “flavonoids”.11 Flavonoids are secondary metabolites of
plants; share a common carbon skeleton of two benzene rings, linked by a 3-carbon bridge (C6–
C3–C6).12 Flavonoids include various subclasses, among them flavonols (quercetin and
kaempferol), flavones (luteolin and apigenin), flavanols (catechins and proanthocyanidins),
anthocyanidins, flavanones (naringenin and hespertine), and isoflavones (genistein and daidzein)
are commonly found in different foods especially fruits.13
Treatment of kaempferol (10 μM) a fruit flavonol significantly increased the viability,
reduced cellular apoptosis and caspase-3 activity in human beta cells and islets. Furthermore,
kaempferol treatment also increased the expression of anti-apoptotic proteins (Bcl-2 and
Akt) (Zhang and Liu, 2011)14. In addition, studies also demonstrated that quercetin flavonoid
increase the regeneration of pancreatic islets and ultimately increase the insulin secretion in
streptozotocin-induced diabetic rats.11
COMMONLY USED THERAPIES AGAINST DIABETES AND THEIR RELATED
PROBLEMS
No cure for diabetes is yet to be found, but currently use pharmacological and non-
pharmacological therapeutic measures have positively enhanced the life quality of individuals
suffering from diabetes and its micro and macro-vascular complications.15 Diabetes is a disorder
that needs continuous medical attention, support, and self-management education of the patient
to avoid serious complications and to diminish the risk of long-term complications; accordingly
its management is complex and needs many issues, beyond glycemic control, to be addressed.16
As diabetes is a disorder characterized by chronically increased levels of blood glucose. The
currently used antidiabetic treatments have largely fixed the glucose problem. In fact, all
7
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
currently used anti-diabetic agents in practice work directly and indirectly by regulating the
blood glucose level (Figure 1). They include:
Insulin administration in type 1 diabetes mellitus patients due to auto-destruction of β-
cells of pancreas and ultimately incapability of cells to secrete insulin and for type 2
diabetic patients, in which cells are unable to respond the normal action of circulating
insulin and incapable to meet safe glycemic targets.17
Sulfonylureas are the antidiabetic drugs (glibenclamide and glyburide) that increase the
amount of insulin by acting upon the β-cells of pancreas. On β-cells membrane they
attached to an ATP-dependent K+(KATP) and cause positive electric potential over the
membrane and open the Ca2+ channels. This elevation of intracellular calcium ions results
into increased fusion of insulin granule with cell membrane, henceamplifiedthe secretion
of insulin.18 Incretins like exenatide and liraglutide also increase the insulin production by
acting on pancreas.19
Biguanides and thiazolidinediones increase the insulin sensitivity of adipose tissue, liver,
and muscle by increasing the uptake of glucose in muscle and decrease the production of
glucose in liver. They include metformin and pioglitazone.20,21
Acarbose and miglitol are the antidiabetic agents that slowdown the absorption of glucose
from gastrointestinal tract. Nutritional supplements also inhibits α-glucosidase and α-
amylase activity in gut and ultimately reduce the glucose uptake.22,23
Bariatric surgery, especially when the lifestyle and pharmacologic interventions become
unable to control diabetes or its related problems.24
8
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
The clinical evaluation of a patient helps to select the suitable therapy for the treatment. All the
above mention preventive measures fulfill their objective to some extent except bariatric
surgery.24 Diabetes and it related complications are not cured till now.
Unfortunately, Tthe present treatments of for diabetes through anti-diabetic agents have their
own flaws including the increased resistance and lack of responsiveness in a large segment of the
patient population. In addition, not any antihyperglycemic agent properly controlstackles the
elevated lipid level that is common in this disease.25
The above mention antidiabetic drugs impose serious side effects on human heath, so the need of
antidiabetic agent primarily from natural source is of prime importance.26 Most of these oral
antidiabetic agents impose serious side effects so, diabetes management without any adverse
effect is still a challenge.8 Therefore, holistic exploration of more active and safer therapeutic
agents in eliminating diabetic syndromes is an important area of investigation.9
FLAVONOIDS: POTENTIAL ANTI-DIABETIC AGENTS
Recently, more attention is given on research of flavonoids from dietary sources, due to growing
evidence of their versatile health benefits. To best understand the mode of action of flavonoids as
their potential role in the prevention of diseases, it is important to know their biosynthesis,
metabolism, and bioavailability.27
Natural products from fruit and vegetable sources are becoming popular worldwide and
broadly accepted as an aid to conventional therapy.10 Increasing public awareness and scientific
interest headed the research towards the evaluation of fruits role in health up-gradation and
disease treatment. In recent years, great attention has been focused on the health promoting roles
of bioactive components known as “flavonoids”.11 Flavonoids are ubiquitously secondary
9
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
metabolites present in almost all fruits and vegetables.N - 23 They share a similar carbon skeleton of
two benzene rings, linked by a 3-carbon bridge (C6–C3–C6)12 and include various subclasses
(table 1), notably flavonols (quercetin and kaempferol), flavones (luteolin and apigenin),
flavanols (catechins and proanthocyanidins), anthocyanidins (aurantinidin, cyaniding),
flavanones (naringenin and hespertine), and isoflavones (genistein and daidzein).13
Please make a table
Class of Flavonoid General Structure Different members with their
sources
Flavonoids have various positive effects on complex metabolic pathologies including
diabetes, through multifarious modes of actions.N-24 It is postulated that majority of the
bioactivity of flavonoids is due to their α,β ketones and hydroxyl groups. N - 25
Treatment of kaempferol (10 μM) a fruit flavonol significantly increased the viability,
reduced cellular apoptosis and caspase-3 activity in human beta cells and islets. Furthermore,
kaempferol treatment also increased the expression of anti-apoptotic proteins (Bcl-2 and
Akt) (Zhang and Liu, 2011)14 . In addition, studies also demonstrated that quercetin flavonoid
increase the regeneration of pancreatic islets and ultimately increase the insulin secretion in
streptozotocin-induced diabetic rats.11
10
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
Recently, more attention is given on research of flavonoids from dietary sources, due to growing
evidence of their versatile health benefits. To best understand the mode of action of flavonoids as
their potential role in the prevention of diseases, it is important to know their biosynthesis,
metabolism, and bioavailability.27
BIOSYNTHESIS OF FLAVONOIDS IN PLANTS
Flavonoids belong to the family of aromatic compounds that are derived from phenyl and
malonyl-coenzyme A, through the fatty acid pathway.28 In the beginning of flavonoids
biosynthesis, the phenylalanine (from the shikimic acid pathway) is changed to coumaroyl-CoA
by phenylalanine ammonia-lyase and 4-coumarate (CoA ligase, and cinnamate 4-hydroxylase).
Coumaroyl-CoA is condensed with three molecules of malonyl-CoA (from acetyl-CoA) to
produce naringenin chalcone by chalcone synthase (the first enzyme for flavonoid biosynthesis).
Then chalcone isomerase converts naringenin chalcone to naringenin. Naringenin is further
modified by glycosylation, acylation, and methylation of its three rings. All these enzymatic
steps result into production of substituted flavones, catechins, deoxyflavonoids, flavonols, and
anthocyanins. Isoflavone synthase (cytochrome P450 enzyme) form isoflavonoids from
naringenin or deoxyflavonoids by aryl movement of the B-ring to the 3rd position, then
hydroxylation at the 2nd position. The 2-hydroxyisoflavone is an unstable intermediate molecule
and is dehydrated to produce isoflavone.29
METABOLISM AND BIOAVAILABILITY OF FLAVONOIDS
11
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
Flavonoids are used as substrates by conjugating and hydrolyzing enzymes of small intestine,
liver, and colon. Then these enzymes convert the flavonoids into O-glucuronides, sulfate esters,
and O-methyl esters.30 Flavonoids conjugation is first occurred happened in the small intestine
then in the liver. In liver, they are further metabolized to produce glucuronides and sulfate
derivatives which are then facilitated and excreted through urine and bile.30 The unabsorbed
compounds were further moved to colon and structurally modified by colonic microflora.31 The
flavonoid glucuronides are hydrolyzed into aglycones (by microbiota) after re-entering the
enterohepatic circulation.32 Then aglycones are further breakdown to low molecular compounds
that can easily be absorbed.
Spencer et al.33 reported that during systemic absorption of monomeric flavan-3-ols they
are either metabolized into O-methylated forms or conjugated to form glucuronides or sulphates.
In addition, the monomeric flavan-3-ols (procyanidins) were split into the conjugates of
epicatechin. A study done by Del-Rio et al.31 on the absorption and metabolism of flavan-3-ols in
humans illustrated that epigallocatechin-O-glucuronide and methyl-epicatechin-sulphate were
excreted in urine hence confirmed the above statement. Another recent study done by Fernandes
et al.34 on the bioavailability of an anthocyanin derivative demonstrated the transepithelial
transport of flavan-3-ol-anthocyanin dimer [(+)-catechin-4, 8-malvidin-3-glucoside], by using
Caco-2 cells. The results were compared with (+)-catechin, procyanidin B3 (dimer), and
malvidin-3-glucoside. All the compounds under consideration passed the Caco-2 cell model
barrier and the absorption of catechin-malvidin dimer was significantly less as compared to
individual malvidin or catechins compounds. But the transport efficacy of the catechin-malvidin
dimer was more than procyanidin B3 dimer and this increased transport efficacy of catechin-
malvidin dimer might be due to presence of the anthocyanin and its glucose moiety in the flavan-
12
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
3-ol-anthocyanin. Interestingly, after 2 hour of incubation only the breakdown of parent
compounds was observed and no catechin-malvidin dimer metabolites were found. The results of
this study illustrated that anthocyanins are absorbed as anthocyanin derivatives and catechin-
malvidin dimer is more resistant to metabolism as compared to its parent compounds. A study
done on the genistein (aglycone) and its glycoside genistin bioavailability showed that the
bioavailability of the aglycone was higher in comparison to its glycoside form.35
PROMISING ANTIDIABETIC ROLE OF FRUITS FLAVONOIDS
Numerous studies demonstrated that many plants especially fruits are traditionally used for the
treatment of diabetes.36,37 Epidemiological studies and meta- analyses described that use of fruits
rich in flavonoids (found in fruits) utilization decreased the age related disorder especially
diabetes.38,39 Plenty ofMany in- vitro and animal studies support the worthy positive effects of
various fruits flavonoids on glucose homeostasis.40-46 These Generally flavonoids exert wide
range of their antidiabetic activity on various organs especially work as antidiabetic agents by
ameliorating the insulin action on skeletal muscle and liver cells. They to reduce the plasma free
fatty acid level, hepatic gluconeogenesis, and increased glucose uptake.47 In the intestine,
flavonoids inhibit the digestion of starch, slow down the gastric emptying and reduce the
absorption of glucose across the membrane.48 The proposed antidiabetic mechanism of fruits
flavonoids is presented in Figure 2. The fruits flavonoids and their antidiabetic roles are
presented in Table 1.
Citrus flavonoids as antidiabetic agent
In recent years, citrus flavonoids gained much attention because of their potential therapeutic
properties and comparatively low toxicity to animals.49-51 Shen et al.52 reported that citrus
13
240
241
242
243
244
245
246247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
flavonoids like hesperidin, nobiletin, neohesperidin, and naringin showed antidiabetic properties
by binding starch and slow down its digestion. Numerous studies reported that hesperidin,
naringin, and nobiletin enhanced the insulin sensitivity and induced the hypoglycemic effect in
diabetic animals.46,53-56 Naringenin a major flavonoid found in citrus possessed antidiabetic
properties. Lim et al.57 demonstrated that naringenin exhibited insulin sensitive effect at a
concentration of 100 µM, by enhancing the uptake of glucose in primary rat adipocytes (163%)
as compared to insulin (130%). The studies of Huong et al.58 demonstrated that fruits rich in
naringenin (1%) improved the oxidation of hepatic fatty acid by regulating the gene that encodes
the enzyme for peroxisomal β-oxidation in mice and this change may account for its capability of
inducing low serum lipid levels. Moreover, naringenin reduced the lipid level by increasing the
low density lipoprotein receptor expression through phosphatidylinositol 3-kinase facilitated up
regulation of sterol regulatory element-binding protein.59
Phosphoenolpyruvate carboxykinase and glucose 6-phosphatase are the main enzymes
involved in gluconeogenesis. In diabetic condition, the levels of these enzymes raise which lead
to reduce utilization of glucose and elevated production of glucose.60 Naringin and hesperidin
belongs to citrus flavonoids and suppressed the expression of phosphoenolpyruvate
carboxykinase and glucose 6-phosphatase, and reduced the hepatic glucose production.46
Berries flavonoids as antidiabetic agent
Procyanidin extract of grapes seeds increased the concentration of insulin transporter:
glucose transporter-4 in plasma membrane, increased the uptake of glucose in adipocytes, and
ultimately induced the antihyperglycemic effect in streptozotocin-induced diabetic rats.61 Glucose
transporter-4 is the main insulin regulating transporter which is expressed in skeletal muscle and
14
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
adipose tissue. In diabetic db/db mice adipocyte, the expression of glucose transpoter-4 improves
the glycemic control by ameliorating insulin resistance.62
Cai et al. 41 reported the antidiabetic effect of epigallocatechin gallate on glucose-induced
toxicity in the pancreatic β-cells of a rat insulinoma-m5F cells. The results demonstrated that 0.1
and 10 μM concentration of epigallocatechin gallate enhanced insulin secretory function and
viability of β-cells in glucotoxic conditions. These properties were partially facilitated via
increased expression of insulin receptor substrate-2, the forkhead box protein O1, Akt (glucose
metabolizing protein kinase), and pancreatic duodenal homeobox1.Insulin receptors substrate
protein mediates the insulin action and regulates the β-cells viability and proliferation. The
forkhead box protein O1 regulates the cellular proliferation and protects the β-cells from
apoptosis.63 Pancreatic duodenal homeobox1 is a transcription factor that is expressed in islets of
Langerhans and increase the viable count of islets.64
Strawberry is a fruit of nutritional importance and now gaining attention because of
antidiabetic property of its flavonoids.65,66 In general α-amylase and α-glucosidase are the key
enzymes involved in catalytic breakdown of carbohydrates into glucose. In antidiabetic analyses,
IC50 value for α-amylase and α-glucosidase activity of fruit extract of strawberry was found to be
86.47 ± 1.12μg/ml and 76.83 ± 0.93μg/ml respectively. Maximum inhibition of 52.35% at a
concentration of 97μg/μL was done by strawberry extract (rich in phytochemicals) and in
comparison with standard acarbose, which exhibited maximum inhibition of 72.10% at a
concentration of 92μg/μL. In addition, at the concentration of 91μg/μL, strawberry extract
induced 58.83% of inhibition. Standard acarbose exhibited maximum inhibition of 69.43% at a
concentration of 96μg/μL.67 The studies also demonstrated the antidiabetic effects of bayberry
fruit extract. Sun et al.68 reported that bayberry extract (rich in cyanidin-3-glucoside) decreased
15
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
the risk of oxidative stress and ultimately reduced the β-cell damage. Initial treatments of β-cells
with bayberry fruit extract (comprising 0.5μM cyanidin-3-glucoside) stopped cell death by
hydrogen peroxide, mitochondrial reactive oxygen species production, and cell necrosis.
The bioactive components present in the most of berries and cherries appear as
glycosides of anthocyanidins. Dried cherries of Cornus spp. have been traditionally used for
diabetes treatment in China.69 The cyanidin-, delphinidin-, and pelargonidin glycosides are the
important bioactive component of Cornus fruits.70,71 These anthocyanidins and anthocyanins
components improved the insulin secretion by acting on β-cells of pancreas. The pancreatic β-
cells were treated with cyanidin-3-glucoside and delphinidin-3-glucoside for 60 minute and they
increased the glucose stimulated insulin secretion. While pelargonidin-3-galactoside, cyanadin-3-
galactoside, and aglycones: cyanidin, pelargonidin, delphinidin, and malvidin had negligible to
marginal effects on glucose stimulated insulin secretion.72 Cyanidin 3-glucoside (50 μM) and
protocatechuic acid improved the glucose uptake and translocation of glucose transporter in
human and rat adipocytes.73
Rostamian et al.74 demonstrated the antidiabetic action of hydroalcoholic extract of
strawberries leaves rich in flavonoids. For this purpose 24 male adult rats were selected
randomly and were divided into non antidiabetic control group, diabetic control, and diabetic
group. Diabetic group was administered with alloxan then intraperitoneally injected with extract
(100mg/Kg). The analysis of glucose, triglyceride, high density lipoprotein, cholesterol, and low
density lipoprotein content showed that the extract rich in flavonoids meaningfully reduced the
glucose, triglyceride, cholesterol, and elevated the level of high density lipoproteins but didn’t
affect the low density lipoprotein content.
16
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
Eid et al.75 elucidated the mode of action of quercetin rich extract of Vaccinumvitis-idaea
(cowberry) in the treatment of diabetes. For this purpose 10 compounds (found in berries)
involved in glucose absorption were analyzed in C2C12 murine skeletal myoblasts and H4IIE
murine hepatocytes (main cells of liver tissue). The results revealed that quercetin-3-O-glycoside
and quercetin aglycone were the active components involved in glucose absorption. This effect is
facilitated by adenosine monophosphate activated protein kinase, which mediates the
translocation of glucose transporter type 4. Adenosine monophosphate activated protein kinase is
an energy sensing molecule and involve in body energy homeostasis. It improves the glycemic
level and lipid profile in insulin resistant rodents.76 Therefore, adenosine monophosphate
activated protein kinase is considered as an attractive target for developing new strategies to treat
diabetes.
Bilberries are the rich source of anthocyanins.77,78 Takikawa et al.78 elucidated the
metabolic properties of bilberry extract (27g bilberry extract containing 10g anthocyanin/Kg
diet) in mice with type 2 diabetes. Bilberries extract enhanced hypoglycemia and insulin
sensitivity in diabetic mice by targeting adenosine monophosphate activated protein kinase,
glucose transporter type 4, and other metabolic enzymes.
Persimmon flavonoids as antidiabetic agent
The persimmon belongs to the family of Ebenaceae and inhabitant of Japan and China. Several
studies demonstrated the antidiabetic and antiobesity effects of persimmon flavonoids.79,80
Proanthocyanidin, a major flavonoid obtained from persimmon peel was reported to possess
antidiabetic and antiobesity properties. Administration of proanthocyanidin (from persimmon
peel) to streptozotocin-induced diabetic rats reduced the elevated level of lipid peroxidation,
17
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
inhibited the reactive oxygen species generation, reduced the serum glucose, glycosylation of
hemoglobin, urinary protein, glycation products, and serum urea nitrogen. Hence, this protective
effect of proanthocyanidin showed its antidiabetic potentials.81 In addition, Dewanjee et al.79
reported that proanthocyanidin elevated the level of super oxide dismutase, glutathione, and
catalase activity in the liver and kidney, and finally prevent the oxidative stress mediated diabetic
complications in this severe diabetic model.
Matsumoto et al.80 demonstrated that persimmon significantly reduced the elevation in
plasma lipids (total cholesterol, LDL cholesterol, and triglyceride) in the diet-induced obesity
mouse model. Moreover, Lee at al.82 reported that proanthocyanidin, reduced the plasma glucose,
glycosylation of protein, and hyperlipidemia and ultimately reduced the hyperglycemia in male
db/db mice (leptin receptor deficient). Proanthocyanidins polymers showed a strong inhibitory
effect on α-amylase, while oligomers induced a stronger protective effect against α-glucosidase
activity and angiotensin converting enzyme formation, suggesting that oligomers may have more
potential as anti-diabetic agents. Moreover, persimmon proanthocyanidin also reduced the
elevated oxidative stress in db/db mice by reducing the lipid peroxidation, reactive oxygen
species, protein expression of inducible nitric oxide synthase, and cyclooxygenase-2 and
improved the glutathione/oxidized ratio.81 Inducible nitric oxide synthase mediate inflammation-
related insulin resistance. Cyclooxygenase-2 is the enzyme involved in β-cell dysfunction. Gu et
al.83 reported the antidiabetic effect of tannins extracted from persimmon pulp. The results
demonstrated that tannins exhibited their activity by scavenging the hydroxyl radical and induced
the antioxidant effect. Overall, the studies proposed that proanthocyanidin polymerization has
ability to combat the obese and diabetic phenotype, and that its oligomers are the more potent
and promising compounds.
18
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
Guava flavonoids as antidiabetic agent
Guava is tropical fruit and rich source of natural antioxidants like, vitamin C and polyphenolic
compounds.84,85 Numerous studies have demonstrated that the leaves and fruit of guava induced
antidiabetic effects in alloxan- or streptozotocin-induced diabetic models.86,87
Wu et al.88 demonstrated the antiglycation activity of guava leaves extract and its active
compounds. The results revealed that guava leaves extract and its compounds inhibited the
process of glycation in albumin and their potency was compared with polyphenol 60
(polyphenolic compound extracted from plants) and antiglycation agent (aminoguanidine). The
results revealed that inhibitory effect of guava leaf extracts against α-dicarbonyl compounds
formation were over 95% at 50μg/mL. The guava leaf extracts also induced strong inhibition on
the generation of amadori product (intermediate product in advance glycation end product
formation) and advance glycation end products in albumin in the presence of glucose. The
catechins and quercetin induced 80% of the antiglycated effect. Among all the phenolic
compounds that were under study, quercetin showed highest activity (95%) at 100μg/mL and no
activity was shown by ferulic acid.
Cheng et al.86 isolated quercetin flavonoid from aqueous extract of guava leaves by
column chromatography and analyzed its efficacy. The results revealed that quercetin separated
from the guava leaves extract increased the glucose uptake in rat clone 9-hepatocytes (liver
cells). So quercetin contributes to mitigate hyperglycemia in diabetes as a consequence.
Shen et al.89 reported the antidiabetic effect of aqueous and ethanolic extracts of guava
leaves in low-dose streptozotocin and nicotinamide-induced rats. The results indicated that
aqueous extract increased the activities of hepatic hexokinase, phosphofructokinase, and glucose-
19
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
6-phosphate dehydrogenase in diabetic rats as compared to the normal diabetic group.
Furthermore, ethanolic extract only elevated the hepatic hexokinase and glucose-6-phosphate
dehydrogenase activity in diabetic rats. Due to these effects of the extracts, the assimilation of
glucose in glycolytic pathway and pentose monophosphate shunt was increased and resulted into
depression of the blood glucose level. Huang et al.90 demonstrated the blood glucose lowering
effect of guava in streptozotocin-induced diabetic rats. They reported that guava induced its
hypoglycemic effect by protecting the viability of β-cells from lipid peroxidation and breakdown
of DNA strands and ultimately improved the insulin secretion. In addition, guava also inhibited
the expression of pancreatic nuclear factor-kappa B protein and improved the activities of
superoxide dismutase, catalase, and glutathione peroxidase, which are involved in antioxidant
activity. Begum et al.91 identified more than 20 compounds in guava fruit extract. In addition,
studies reported the positive correlation between antihyperglycemic activity and phenolic content
especially flavonoids in fruits.92
Wang et al.93 reported the inhibitory activity of guava leaves extract against α-amylase
and α-glucosidase. Seven flavonoids (quercetin, guaijaverin, avicularin, kaempferol, hyperin,
apigenin, and myricetin) were isolated from the ethanolic and butanolic extracts of guava leaves
extract. The study revealed that querticin, kaempferol, and myricetin flavonoids showed highest
inhibitory activity against sucrase with IC50 values of 3.5 mM, 5.2 mM, and 3.0 mM, against
maltase with IC50 values of 4.8 mM, 5.6 mM, and 4.1 mM and against α-amylase with
IC50 values of 4.8 mM, 5.3 mM, and 4.3 mM, respectively. Among these flavonoids, myricetin
(1.5 mg/mL) exhibited the highest inhibition of 70% against sucrase. The results suggested that
hydroxyl groups play an important role in the inhibition activity.
20
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
Papaya Flavonoids as Antidiabetic Agents
Quercetin 3-O-rutinoside and mangiferingallate were the major flavonoids present in papaya.94,95
Sellamuthu et al.96 also reported that papaya is rich source of mangiferin and the galloylated
forms of mangiferin and isomangiferin, xanthone glycosides. These phytochemicals were
described as potent antidiabetic agents.
Sasidharan et al.97 demonstrated the antidiabetic effect of ethanolic extract of Carica
papaya in streptozotocin-induced diabetic rats. Phytochemical screening revealed that this effect
was probably due to the presence of certain phytochemical especially flavonoids. The
phytochemicals rich extract increased the regeneration of β-cells of pancreas, improved the
function of liver tissue, and the recovery of cuboidal tissue of kidney.
Juarez-Rojop et al.98 reported that aqueous extract of Carica papaya increased the
secretion of insulin by acting on β-cells. A treatment with Carica papaya significantly reduced
the serum triglycerides, cholesterol, and aminotransferases in diabetic rats. Aqueous extract
improved the morphology of hepatocytes by preventing the cells disruption and inhibition of
glycogen and lipid accumulation.
Miscellaneous
Eugenia jambolana (jamun) is long known for its antidiabetic activities in traditional medicines.
Sharma et al.99 study the effect of flavonoid rich extract of seeds of Eugenia jambolana on
streptozotocin-induced diabetic mice. The results demonstrated that flavonoid rich extract
improved the glucose tolerance, glycogen synthesis, glucose absorption, lipid profile, and insulin
release in extract treated subject. In addition, expression and regulation of glucose-6-phosphatase
21
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
and hexokinase also changed in response to the flavonoid rich extract. This showed the
hypoglycemic and hypolipidemic effect of flavonoid rich extract of Eugenia jambolana.
Rojo et al.100 studied the antidiabetic effect of standardized anthocyanin-rich formulation
from Maqui Berry (Aristotelia chilensis) in type 2 diabetic mice model. They also demonstrated
the antidiabetic effect of delphinidin 3-sambubioside-5-glucoside (obtained from Maqui Berry).
Oral administration of anthocyanin-rich formulation decreased the fasting blood glucose levels
and glucose tolerance in hyperglycemic obese mice (fed with high fat diet). In addition, ANC
decreased the glucose production by reducing the expression of glucose-6-phosphatase. The oral
administration of delphinidin 3-sambubioside-5-glucoside in combination with ANC reduced the
fasting blood glucose level, increased the glucose absorption in L6 myotubes and lessened the
glucose production in H4IIE rat liver.
“Punica granatum” is a traditional hypoglycemic plant, commonly known as
pomegranate.101 The connection between pomegranate and its diabetic effects are well discussed
by Katz et al.102 They revealed that pomegranate extracts and their active components possessed
strong antidiabetic properties. Therapeutic103 and cardioprotective effect104 of pomegranate, and
its juice were also reported. Furthermore, Koren-Gluzer et al.105 reported that pomegranate juice
in combination with 50 μmol/L punicalagin, amplified the insulin production from a β-tumor cell
line. This property is similar to the activity of the paraoxonase 1 enzyme. Moreover,
administration of pomegranate fruit extract with ellagic acid (50–10μg/mL) to differentiated
murine 3T3-L1 adipocytes has significantly decreased the production and intracellular levels of
resistin by encouraging its degradation at the protein level.106
22
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
CONCLUDING THOUGHTS AND FUTURE RESEARCH
TRENDSCHALLENGES
Research on diabetes and its management has been of continued interest among the scientists for
the last many decades. Importance of research on diabetes is evident from the fact that 7 Nobel
prizes to 10 scientists have been awarded on various ground breaking discoveries related to
diabetes. Ironically, from public health perspective, diabetes is still a challenge and associated
with reduced life expectancy due to obscurity of its cure despite of intervening research within
the last two centuries.
Management of diabetes through diet is a potential area of research. Compelling evidence from
epidemiological studies and in vitro and vivo trials has converged that several fruits possessed
antidiabetic effects due to the presence of certain bioactive components like flavonoids. It is
encouraging that some of the flavonoids are comparable in function to the clinically used
antidiabetic drugs. Investigation to better understand biochemical nature of antidiabetic effects of
flavonoids may lead to the discovery of novel natural source for the management of diabetes
with minimal side effects. Fruit flavonoids possess various anti-diabetic, anti-inflammatory and
antioxidant potentials and act on various cellular signaling pathways in pancreas, white adipose
tissue, skeletal muscle, and liver and induce antidiabetic effects. Antidiabetic effects of these
flavonoids might be due to antioxidant, receptor agonist or antagonist activity, enzyme inhibition
or through other novel mechanisms still to be demonstrated. Unlike synthetic anti-diabetic
agents, fruit flavonoids manage diabetes without compromising cellular homeostasis thereby
posing no side effects. Further studies are needed to understand the structure-activity
relationships of flavonoids to find whether and how flavonoid molecules interact with the
cellular components.
23
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
Holistic corrective actions of fruit flavonoids to combat the complexities of diabetes mellitus are
advantageous over the chemical antidiabetic agents which have solitary actions and are notorious
to disrupt metabolic equilibrium. Advances in isolation, purification and characterization of
bioactive compounds from fruits should be employed and flavonoids should be isolated from
fruits and tested for their dose dependent efficacy studies in animal and human models to
develop a natural and sustainable approach to mange diabetes mellitus. pharmaceutical
treatments for diabetes.
Large clinical trials on humans are required to validate the plant based therapies for diabetes.
(MORE ELABORATION NEEDED) Coherent series of experiments are needed to formulate
dietary guidelines that can be really helpful for people with diabetes to manage this devastating
disease. Disparities among the different organizations groups should be addressed on the basis of
evidence based dietary recommendations to present holistic and simplified picture to diabetic
patients.
CONCLUSION
Epidemiological studies in vitro and vivo revealed that several fruits possessed antidiabetic effect
due to the presence of certain bioactive components like flavonoids. Flavonoids act on various
cellular signaling pathways in pancreas, white adipose tissue, skeletal muscle, and liver and
induce antidiabetic effects. Antidiabetic effects of these flavonoids might be due to antioxidant,
receptor agonist or antagonist activity, enzyme inhibition or through other novel mechanisms
still to be demonstrated. It is encouraging that some of the flavonoids are comparable in function
24
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
to the clinically used antidiabetic drugs and their antidiabetic effect is further evaluated for
generation of novel natural antidiabetic drug.
25
514
515
516
REFERENCES
N-1 Shi, Y., and F. B. Hu. 2014. The global implications of diabetes and cancer. The Lancet 383:1947-1948.
N-2 Danaei, G., M. M. Finucane, Y. Lu, G. M. Singh, M. J. Cowan, C. J. Paciorek, J. K. Lin, F. Farzadfar, Y.-H. Khang, G. A. Stevens, M. Rao, M. K. Ali, L. M. Riley, C. A. Robinson, and M. Ezzati. 2011. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. The Lancet 378:31-40.
N-3 Alwan, A. 2011. Global status report on noncommunicable diseases 2010. World Health Organization.
N-4 World Health Organization. 2006. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization:1-50.
N-5 Merck Manual. 2010. Diabetes Mellitus and Disorders of Carbohydrate Metabolism in Merck Manual Professional. Merck Publishing.
N-6 Rother, K. I. 2007. Diabetes Treatment — Bridging the Divide. New England Journal of Medicine 356:1499-1501
N-7 World Health Organization. 1999. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Department of Noncommunicable Disease Surveillance, World Health Organization, Geneva. 1-59.
N-8 Mendis, S., L. H. Lindholm, G. Mancia, J. Whitworth, M. Alderman, S. Lim, and T. Heagerty. 2007. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. Journal of hypertension 25:1578-1582.
N-9 Mendis, S., and O. Chestnov. 2014. The global burden of cardiovascular diseases: a challenge to improve. Curr Cardiol Rep 16:486-493.
N-10 Boden-Albala, B., S. Cammack, J. Chong, C. Wang, C. Wright, T. Rundek, M. S. V. Elkind, M. C. Paik, and R. L. Sacco. 2008. Diabetes, Fasting Glucose Levels, and
26
517
518
519520
521522523524525526
527528
529530531
532533
534535
536537538539
540541542543544
545546
547548
Risk of Ischemic Stroke and Vascular Events: Findings from the Northern Manhattan Study (NOMAS). Diabetes Care 31:1132-1137.
N-11 Levitan, E. B., Y. Song, E. S. Ford, and S. Liu. 2004. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease?: A meta-analysis of prospective studies. Archives of Internal Medicine 164:2147-2155
N-12 Icks, A., B. Haastert, C. Trautner, G. Giani, G. Glaeske, and F. Hoffmann. 2009. Incidence of Lower-limb Amputations in the Diabetic Compared to the Non-diabetic Population. Findings from Nationwide Insurance Data, Germany, 2005–2007. Exp Clin Endocrinol Diabetes 117:500-504.
N-13 Resnikoff, S., D. Pascolini, D. Etya'ale, I. Kocur, R. Pararajasegaram, G. P. Pokharel, and S. P. Mariotti. 2004. Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 82:844-851
N-14 Lee, I. M., E. J. Shiroma, F. Lobelo, P. Puska, S. N. Blair, and P. T. Katzmarzyk. 2012. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. The Lancet 380:219-229.
N-15 Willi, C., P. Bodenmann, W. A. Ghali, P. D. Faris, and J. Cornuz. 2007. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. The Journal of the American Medical Association 298:2654-2664.
N-16 Adler, A. I., I. M. Stratton, H. A. Neil, J. S. Yudkin, D. R. Matthews, C. A. Cull, A. D. Wright, R. C. Turner, and R. R. Holman. 2000. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419.
N-17 Riserus, U., W. C. Willett, and F. B. Hu. 2009. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res 48:44-51.
N-18 Malik, V. S., B. M. Popkin, G. A. Bray, J.-P. Després, and F. B. Hu. 2010. Sugar-Sweetened Beverages, Obesity, Type 2 Diabetes Mellitus, and Cardiovascular Disease Risk. Circulation 121:1356-1364.
N-19 The Diabetes Control and Complications Trial Research Group 1995. The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy. Annals of Internal Medicine 122:561-568
N-20 Paulweber B et al. for the Writing Group, on behalf of the IMAGE Study Group. A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes. Hormone and Metabolic Research, 2010; 42 (Suppl.1): S3–S36.
27
549550
551552553
554555556557
558559560
561562563
564565566
567568569570
571572
573574575
576577578
579580581
N-21 Robinson, M. K. 2009. Surgical treatment of obesity--weighing the facts. N Engl J Med. 30;361(5):520-521
N-22 Maciejewski, M. L., E. H. Livingston, V. A. Smith, and et al. 2011. SUrvival among high-risk patients after bariatric surgery. JAMA 305:2419-2426
N-23 Ramos, Y. 2012. Report of The Endocrine Society’s 94th Annual Meeting in Houston. Retrieve from https://www.endocrine.org/news-room/press-release-archives/2012/type-2-diabetes-cured-by-weight-loss-surgery-returns-in-onefifth-of-patients
N-23 Chen, M. H., C. H. Lin, and C. C. Shih. 2014. Antidiabetic and Antihyperlipidemic Effects of Clitocybe nuda on Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice. Evidence-Based Complementary and Alternative Medicine 2014.
N-24 Veerapur, V. P., K. R. Prabhakar, M. R. Kandadi, K. K. Srinivasan, and M. K. Unnikrishnan. 2010. Antidiabetic effect of Dodonaea viscosa aerial parts in high fat diet and low dose streptozotocin-induced type 2 diabetic rats: A mechanistic approach. Pharmaceutical Biology 48:1137-1148.
N-25 Havsteen, B. H. 2002. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96:67-202.
1. Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycemia in type 2
diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus
statement of the American diabetes association and the European association for the study of
diabetes. Diabetes Care. 2009;32:193–203.
2. Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents? Int J
Clin Pract. 2009;63:321–332.
3. Akkati S, Sam KG, Tungha G. Emergence of promising therapies in diabetes mellitus. J Clin
Pharmacol. 2011;51:796–804.
4. Rizvi SI, Mishra N. Traditional Indian medicines used for the management of diabetes
mellitus. J Diabetes Res. 2013;2013:01–11.
28
582583
584585
586587588589
590591592593
594595596597
598599
600
601
602
603
604
605
606
607
608
609
610
5. Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes
Res Clin Practice. 2010;87:15–19.
6. Zierath JR, Wallberg-Henriksson H. From receptor to effector: insulin signal transduction in
skeletal muscle from type II diabetic patients. Ann N Y Acad Sci. 2002;967:120–134.
7. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Drugs. 2005;65:385–411.
8. SaxenaA, Vikram NK. Role of selected Indian plants in management of type 2 diabetes: a
review. J Altern Compl Med. 2004;10:369–378.
9. Liu Q, Chen L, Hu L, et al. Small molecules from natural sources, targeting signaling
pathways in diabetes. Biochim Biophys Acta. 2010;1799:854–865.
10. Kao YH, Hiipakka RA, Liao S. Modulation of endocrine systems and food intake by green
tea epigallocatechin gallate. Endocrinology. 2000;141:980–987.
11. Vessal M, Hemmati M, Vasei M. Antidiabetic effects of quercetin in streptozotocin-induced
diabetic rats. Comp Biochem Physiol C Toxicol Pharmacol. 2003;135:357–364.
12. Aherne SA, O'Brien NM. Dietary flavonols: chemistry, food content, and metabolism. Nutr.
2002;18:75–81.
13. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr.
2000;130:2073S–2085S.
14. Barone E, Calabrese V, Mancuso C. Ferulic acid and its therapeutic potential as a hormetin
for age-related diseases. Biogerontology. 2009;10:97–108.
15. Mohan S, Nandhakumar L. Role of various flavonoids: hypotheses on novel
approach to treat diabetes. J Med Hypotheses Ideas. 2014;8:1 –6.
29
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
16. ADA. American Diabetes Association. Standards of medical care in diabetes – 2011.
Diabetes Care. 2011;34:S11–S61.
17. Henriksen EJ. Dysregulation of glycogen synthase kinase-3 and the etiology of insulin
resistance and type 2 diabetes. Curr Diabetes Rev. 2010;6:285–293.
18. Bodmer M, Meier C, Jick SS, et al. Metformin, sulfonylureas, or other antidiabetes drugs and
the risk of lactic acidosis or hypoglycemia. Diabetes care. 2008;31:2086–2091.
19. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment.
Pharmacol Rev. 2008;60:470–512.
20. Molavi B, Rassouli N, Bagwe S, et al. A review of thiazolidinediones and metformin in the
treatment of type 2 diabetes with focus on cardiovascular complications vascular health and
risk management: 2007;3:967–973.
21. Bourron O, Daval M, Hainault I, et al. Biguanides and thiazolidinediones inhibit stimulated
lipolysis in human adipocytes through activation of AMP-activated protein kinase.
Diabetologia. 2010;53:768–778.
22. Catalan VS, Couture JA, LeLorier J. Predictors of persistence of use of the novel antidiabetic
agent acarbose. Arch Intern Med. 2001;161:1106–1112.
23. Spengler M, Schmitz H, Landen H. Evaluation of the efficacy and tolerability of acarbose
in patients with diabetes mellitus. Clin Drug Investig. 2005;25:651–659.
24. Dixon JB, O’Brien PE, Playfair J. Adjustable gastric banding and conventional therapy for
type 2 diabetes: a randomized controlled trial. J Am Med Assoc. 2008;299:316–323.
25. Zia T, Hasnain SN, Hasan SK. Evaluation of the oral hypoglycemic effect of Trigonella
foenum-graecumin normal mice. J Ethanopharmacol. 2001;75:191–195.
30
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
26. Chitra V, Venkata KR, Varma P, et al. Study of antidiabetic and free radical scavenging
activity of the seed extract of strychnosnux-vomica. Int J Pharm Pharm Sci. 2010;2:106–110.
27. Hollman PCH. Absorption, bioavailability, and metabolism of flavonoids. Pharm Bio.
2004;42:74–83.
28. Shirley BW. Flavonoid biosynthesis: a colorful model for genetics, biochemistry, cell
biology, and biotechnology. Plant Physiol. 2001;126:485–493.
29. Woo HH, Jeong BR, Hawes MC. Flavonoids: from cell cycle regulation to biotechnology.
Biotech Lett. 2005;27:365–374.
30. Landete JM. Updated knowledge about polyphenols: functions, bioavailability, metabolism,
and health. Crit Rev Food Sci Nutr. 2012;52:936–948.
31. Del-Rio D, Calani L, Scazzina F, et al. Bioavailability of catechins from ready-to-drink tea.
Nutr. 2010;26:528–533.
32. Scalbert A, Morand C, Manach C, et al. Absorption and metabolism of polyphenols in the
gut and impact on health. Biomed Pharmacother. 2002;56:276–282.
33. Spencer JP, Schroeter H, Rechner AR, et al. Bioavailability of flavan-3-ols and procyanidins:
gastrointestinal tract influences and their relevance to bioactive forms in vivo. Antioxid
Redox Signal. 2001;3:1023–1039.
34. Fernandes I, Nave F, Gonçalves R, et al. On the bioavailability of flavanols and
anthocyanins: flavanol-anthocyanin dimers. Food Chem. 2012;135:812–818.
35. Steensma A, Faassen-Peters MA, Noteborn HP, et al. Bioavailability of genistein and its
glycoside genistin as measured in the portal vein of freely moving unanesthetized rats. J
Agric Food Chem. 2006;54:8006–8012.
36. Harvey AL. Natural products in drug discovery. Drug Discov Today. 2008;13:894–901.
31
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
37. Sabu MC, Smitha K, Ramadasan K. Anti-diabetic activity of green tea polyphenols and their
role in reducing oxidative stress in experimental diabetes. J Ethnopharmacol. 2002;83:109–
116.
38. Graf BA, Milbury PE, Blumberg JB. Flavonols, flavones, flavanones, and human health:
epidemiological evidence. J Med Food. 2005;8:281–290.
39. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr.
2005;81:317S–325S.
40. Hanhineva K, Torronen R, Bondia-Pons I, et al. Impact of dietary polyphenols on
carbohydrate metabolism. Int J Mol Sci. 2010;11:1365–1402.
41. Cai EP, Lin JK. Epigallocatechin gallate (EGCG) and rutin suppress the glucotoxicity
through activating IRS2 and AMPK signaling in rat pancreatic beta cells. J Agric Food
Chem. 2009;57:9817–9827.
42. Fu Z, Zhang W, Zhen W, et al. Genistein induces pancreatic beta-cell proliferation through
activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice.
Endocrinology. 2010;151:3026–3037.
43. Fu Z, Zhen W, Yuskavage J, et al. Epigallocatechin gallate delays the onset of type 1
diabetes in spontaneous non-obese diabetic mice. Br J Nutr. 2011;105:1218–1225.
44. Zhang Y, Liu D. Flavonol kaempferol improves chronic hyperglycemia-impaired pancreatic
beta-cell viability and insulin secretory function. Eur J Pharmacol. 2011;670:325–332.
45. Zhu W, Jia Q, Wang Y, et al. The anthocyanin cyanidin-3-O-betaglucoside, a flavonoid,
increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen
species during hyperglycemia: involvement of a cAMP-PKA-dependent signaling pathway.
Free Radic Biol Med. 2012;52:314–327.
32
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
46. Jung UJ, Lee MK, Park YB, et al. Effect of citrus flavonoids on lipid metabolism and
glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol.
2006;38:1134–1145.
47. Kannappan S, Anuradha CV. Naringenin enhances insulin-stimulated tyrosine
phosphorylation and improves the cellular actions of insulin in a dietary model of metabolic
syndrome. Eur J Nutr. 2010;49:101–109.
48. Heilbronn L, Smith SS, Ravussin E. Failure of fat cell proliferation, mitochondrial function
and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus.
Obesity. 2004;28:S12–S21.
49. Benavente-Garcia O, Castillo J. Update on uses and properties of citrus flavonoids: new
findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food.
2008;2:6185–6205.
50. Choi EJ, Ahn WS. Neuroprotective effects of chronic hesperetin administration in mice.
Arch Pharm Res. 2008;31:1457–1462.
51. Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus flavonoids pertaining to
cancer and inflammation. Curr Med Chem. 2001;8:135–153.
52. Shen W, Xu Y, Lu YH. Inhibitory effects of citrus flavonoids on starch digestion and
antihyperglycemic effects in HepG2 cells. J Agric Food Chem. 2012;60:9609–9619.
53. Akiyama S, Katsumata S, Suzuki K, et al. Hypoglycemic and hypolipidemic effects of
hesperidin and cyclodextrin-clathrate hesperetin in Goto-Kakizaki rats with type 2 diabetes.
Biosci Biotechnol Biochem. 2009;73:2779–2782.
33
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
54. Akiyama S, Katsumata S, Suzuki K, et al. Dietary hesperidin exerts hypoglycemic and
hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J Clin Biochem
Nutr. 2010;46:87–92.
55. Jung UJ, Lee MK, Jeong KS, et al. The hypoglycemic effects of hesperidin and naringin are
partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J Nutr.
2004;4:2499–2503.
56. Lee YS, Cha BY, Saito K, et al. Nobiletin improves hyperglycemia and insulin resistance in
obese diabetic ob/ob mice. Biochem Pharmacol. 2010;79:1674–1683.
57. Lim SL, Soh KP, Kuppusamy UR. Effects of naringenin on lipogenesis, lipolysis and glucose
uptake in rat adipocyte primary culture: a natural antidiabetic agent. Int J Altern Med.
2008;5:1–10
58. Huong DT, Takahashi Y, Ide T. Activity and mRNA levels of enzymes involved in hepatic
fatty acid oxidation in mice fed citrus flavonoids. Nutr. 2006;22:546–552.
59. Borradaile NM, de-Dreu LE, Huff MW. Inhibition of net HepG2 cell apolipoprotein B
secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-
kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes. 2003;52:2554–
2561.
60. Munoz MC, Barbera A, Dominguez J, et al. Effects of tungstate, a new potential oral
antidiabetic agent, in zucker diabetic fatty rats. Diabetes. 2001;50:131–138.
61. Pinent M, Blay M, Blade MC, et al. Grape seed-derived procyanidins have an
antihyperglycemic effect in streptozotocin-induced diabetic rats and insulinomimetic activity
in insulin-sensitive cell lines. Endocrinology. 2004;145:4985–4990.
34
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
62. Gibbs EM, Stock JL, McCoid SC, et al. Glycemic improvement in diabetic db/db mice by
overexpression of the human insulin-regulatable glucose transporter (GLUT4). J Clin Invest.
1995;95:1512–1518.
63. Buteau J, Accili D. Regulation of pancreatic beta-cell function by the forkhead protein
FoxO1. Diabetes Obes Metab. 2007;9(Suppl 2):140–146.
64. McKinnon CM, Docherty K. Pancreatic duodenal homeobox-1, PDX-1, a major regulator of
beta cell identity and function. Diabetologia. 2001;44:1203–1214.
65. Aaby K, Skrede G, Wrolstad RE. Phenolic composition and antioxidant activities in flesh and
achenes of strawberries (Fragaria ananassa). J Agric Food Chem.2005;53:4032–4040.
66. Hannum SM. Potential impact of strawberries on human health: a review of the science. Crit
Rev Food Sci Nutr. 2004;44:1–17.
67. Mandave P, Rani S, Kuvalekar A, et al. Antiglycation, antioxidant and antidiabetic activity of
mature strawberry (fragaria× ananassa) fruits. Int J ApplBiol Pharm Tech. 2013;4:168–177.
68. Sun CD, Zhang B, Zhang JK, et al. Cyanidin-3-glucoside-rich extract from Chinese bayberry
fruit protects pancreatic beta cells and ameliorates hyperglycemia in streptozotocin-induced
diabetic mice. J Med Food. 2012;15:288–298.
69. Yamahara J, Mibu H, Sawada T, et al. Biologically active principles of crude drugs.
Antidiabetic principles of Cornifructus in experimental diabetes induced by streptozotocin
(author's transl). Yakugakuzasshi. J Pharma Soc Japan. 1981;101:86–90.
70. Jayaprakasam B, Vareed SK, Olson LK, et al. Insulin secretion by bioactive anthocyanins
and anthocyanidins present in fruits. J Agric Food Chem. 2005;53:28–31.
71. Seeram NP, Schutzki R, Chandra A, et al. Characterization, quantification, and bioactivities
of anthocyanins in Cornus species. J Agric Food Chem. 2002;50:2519–2523.
35
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
72. Scazzocchio B, Vari R, Filesi C, et al. Cyanidin-3-O-beta-glucoside and protocatechuic acid
exert insulin-like effects by up-regulating PPAR gamma activity in human omental
adipocytes. Diabetes. 2011;60:2234–2244.
73. Guo H, Xia M, Zou T, et al. Cyanidin 3-glucoside attenuates obesity-associated insulin
resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor
FoxO1. J Nutr Biochem. 2012;23:349–360.
74. Rostamian V, Shakeri F, Estakhr J. The effect of hydro-alcoholic extract of strawberry leaf
on sugar and lipids in serum of diabetic rats. Pharmacologyonline (newsletter). 2011;3:1171–
1175.
75. Eid HM, Martineau LC, Saleem A, et al. Stimulation of AMP activated protein kinase and
enhancement of basal glucose uptake in muscle cells by quercetin and quercetin glycosides,
active principles of the antidiabetic medicinal plant Vacciniumvitis-idaea. Mol Nutr Food
Res. 2010;54:991–1003.
76. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic
syndrome. Cell Metab. 2009;9:407–416.
77. Katsube N, Iwashita K, Tsushida T, et al. Induction of apoptosis in cancer cells by bilberry
(Vaccinium myrtillus) and the anthocyanins. J Agric Food Chem. 2003;51:68–75.
78. Takikawa M, Inoue S, Horio F, et al. Dietary anthocyanin-rich bilberry extract ameliorates
hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in
diabetic mice. J Nutr. 2010;140:527–533.
79. Dewanjee S, Das AK, Sahu R, et al. Antidiabetic activity of Diospyros peregrina fruit: effect
on hyperglycemia, hyperlipidemia and augmented oxidative stress in experimental type 2
diabetes. Food Chem Toxicol. 2009;47:2679–2685.
36
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
80. Matsumoto K, Watanabe Y, Ohya MA, et al. Young persimmon fruits prevent the rise in
plasma lipids in a diet-induced murine obesity model. Biol Pharm Bull. 2006;29:2532–2535.
81. Lee YA, Cho EJ, Tanaka T, et al. Inhibitory activities of proanthocyanidins from persimmon
against oxidative stress and digestive enzymes related to diabetes. J Nutr Sci Vitaminol
(Tokyo). 2007;53:287–292.
82. Lee YA, Cho EJ, Yokozawa T. Effects of proanthocyanidin preparations on hyperlipidemia
and other biomarkers in mouse model of type 2 diabetes. J Agric Food Chem. 2008;56:7781–
7789.
83. Gu H, Li C, Xu Y, et al. Structural features and antioxidant activity of tannin from
persimmon pulp. Food Res Int. 2008;41:208–217.
84. Akinmoladun AC, Obuotor EM, Farombi EO. Evaluation of antioxidant and free radical
scavenging capacities of some Nigerian indigenous medicinal plants. J Med Food.
2010;13:444–451.
85. Thaipong K, Boonprakob U, Cisneros-Zevallos L, et al. Hydrophilic and lipophilic
antioxidant activities of guava fruits. Southeast Asian J Trop Med Public Health.
2005;36:254–257.
86. Cheng FC, Shen SC, Wu JS. Effect of guava (Psidium guajava L.) leaf extract on glucose
uptake in rat hepatocytes. J Food Sci. 2009;74:132–138.
87. Gutierrez RM, Mitchell S, Solis RV, et al. Psidium guajava: a review of its traditional uses,
phytochemistry and pharmacology. J Ethnopharmacol. 2008;117:1–27.
88. Wu JW, Hsieh CL, Wang HY, et al. Inhibitory effects of guava (Psidium guajava L.) leaf
extracts and its active compounds on the glycation process of protein. 2009;113:78–84.
37
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
89. Shen SC, Cheng FC, Wu NJ. Effect of guava (Psidium guajava Linn.) leaf soluble
solids on glucose metabolism in type 2 diabetic rats. 2008;22:1458–1464.
90. Huang CS, Yin MC, Chiu LC. Antihyperglycemic and antioxidative potential of
Psidium guajava fruit in streptozotocin-induced diabetic rats. Food Chem Toxicol.
2011;49:2189–2195.
91. Begum S, Hassan SI, Ali SN, et al. Chemical constituents from the leaves of Psidium
guajava. Nat Prod Res. 2004;18:135–140.
92. Ramkumar KM, Rajaguru P, Latha M, et al. Ethanol extract of Gymnema montanum leaves
reduces glycoprotein components in experimental diabetes. Nutr Res. 2007;27:97–103.
93. Wang H, Du YJ, Song HC. α-glucosidase and α-amylase inhibitory activities of guava
leaves. Food Chem. 2010;123:6–13.
94. Andarwulan N, Kurniasih D, Apriady RA, et al. Polyphenols, carotenoids, and ascorbic acid
in underutilized medicinal vegetables. J Funct Foods. 2012;4:339–347.
95. Rivera-Pastrana DM, Yahia EM, Gonzalez-Aguilar GA. Phenolic and carotenoid profiles of
papaya fruit (Carica papaya L.) and their contents under low temperature storage. J Sci Food
Agric. 2010;90:2358–2365.
96. Sellamuthu PS, Muniappan BP, Perumal SM, et al. Antihyperglycemic effect of mangiferin
in streptozotocin induced diabetic rats. J Health Sci. 2009;55:206–214.
97. Sasidharan S, Sumathi V, Jegathambiga NR, et al. Antihyperglycaemic effects of ethanol
extracts of Carica papaya and Pandanusamaryfollius leaf in streptozotocin-induced diabetic
mice. Nat Prod Res. 2011;25:1982–1987.
38
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
98. Juarez-Rojop IE, Díaz-Zagoya JC, Ble-Castillo JL, et al. Hypoglycemic effect of Carica
papaya leaves in streptozotocin-induced diabetic rats. BMC Compl Altern Med.
2012;12:236.
99. Sharma B, Viswanath G, Salunke R, et al. Effects of flavonoid-rich extract from seeds of
Eugenia jambolana (L.) on carbohydrate and lipid metabolism in diabetic mice. Food Chem.
2008;110:697–705.
100.Rojo LE, Ribnicky D, Logendra S, et al. In vitro and in vivo anti-diabetic effects of
anthocyanins from Maqui Berry (Aristotelian chilensis). Food Chem. 2012;131:387–396.
101.Vidal A, Fallarero A, Pena BR, et al. Studies on the toxicity of Punica granatum L.
(Punicaceae) whole fruit extracts. J Ethnopharmacol. 2003;89:295–300.
102.Katz SR, Newman RA, Lansky EP. Punica granatum: heuristic treatment for diabetes
mellitus. J Med Food. 2007;10:213–217.
103. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern
Med Rev. 2008;13:128–144.
104. Basu A, Penugonda K. Pomegranate juice: a heart-healthy fruit juice. Nutr Rev. 2009;67:49–
56.
105. Koren-Gluzer M, Aviram M, Meilin E, et al. The antioxidant-associated paraoxonase-1
(PON1) attenuates diabetes development and stimulates beta-cell insulin release.
Atherosclerosis. 2011;219:510–518.
106.Makino-Wakagi Y, Yoshimura Y, Uzawa Y, et al. Ellagic acid in pomegranate suppresses
resistin secretion by a novel regulatory mechanism involving the degradation of intracellular
resistin protein in adipocytes. Biochem Biophys Res Commun. 2012;417:880–885.
39
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
107.Zhang Y, Liu D. Flavonol kaempferol improves chronic hyperglycemia-impaired pancreatic
beta-cell viability and insulin secretory function. 2011;670:325–332.
108. Tzeng TF, Liou SS, Liu IM. Myricetin ameliorates defective postreceptor insulin signaling
via beta-endorphin signaling in the skeletal muscles of fructose-fed rats. Evid Based Compl
Altern Med. 2011;2011:150–152.
109. Coskun O, Kanter M, Korkmaz A, et al. Quercetin, a flavonoid antioxidant, prevents and
protects streptozotocin-induced oxidative stress and b-cell damage in rat pancreas. Pharmacol
Res. 2005;51:117–123.
110. Priscilla DH, Roy D, Suresh A, et al. Naringenin inhibits α-glucosidase activity: a promising
strategy for the regulation of postprandial hyperglycemia in high fat diet fed streptozotocin
induced diabetic rats. Chem Biol Interact. 2014;210:77–85.
111. Kim MS, Hur HJ, Kwon DY, et al. Tangeretin stimulates glucose uptake via regulation of
AMPK signaling pathways in C2C12 myotubes and improves glucose tolerance in high-fat
diet-induced obese mice. 2012;358:127–134.
112.Kobayashi Y, Suzuki M, Satsu H, et al. Green tea polyphenols inhibit the sodium-dependent
glucose transporter of intestinal epithelial cells by a competitive mechanism. J Agric Food
Chem. 2000;48:5618–5623.
113. Kumar S, Narwal S, Kumar V, et al. α-glucosidase inhibitors from plants: a natural approach
to treat diabetes. Phcog Rev. 2011;5:19–29.
40
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873